In patients with colorectal carcinoma metastasis, KRAS and NRAS mutations are tested prior to anti-epidermal growth receptor (EGFR) target therapy, as mutated RAS proteins downstream of EGFR will impair treatment effectiveness. This evidence concerns the gene KRAS and colorectal carcinoma.